Top Industry Leaders in the Chromoblastomycosis Treatment Market
Latest Chromoblastomycosis Treatment Companies Updates
Novartis launches antifungal Posaconazole (Noxafil®) injection in India: This expands accessibility of a potent antifungal medication for chromoblastomycosis treatment in a region with high disease burden.
Eisai announces positive Phase 2b trial results for its investigational antifungal agent E1201 for the treatment of chromoblastomycosis: These promising results offer hope for a new treatment option with potentially improved efficacy and tolerability.
AmplyMed receives FDA Fast Track designation for its investigational antifungal Fumagilin for the treatment of chromoblastomycosis: This designation expedites development and regulatory review, potentially bringing a new treatment option to market faster.
List of Chromoblastomycosis Treatment Key companies in the market:
- Astellas Pharma (Japan)
- Biocon Limited (India)
- Abbott Laboratories (U.S.)
- Merck Sharp and Dohme (U.S.)
- Gilead Sciences (U.S.)
- Mylan Labs (U.S.)
- Bristol Myers Squibb (U.S.)
- Bayer AG (Germany)
- Lonza Group (Switzerland)
- Sanofi (France)